+Vote!
Red Orbit (Free subscription) | 06/13/2008
Geron has presented encouraging results from research studies which show that GRNCM1, the company's human embryonic stem cell-based therapeutic for the treatment of heart failure, evades direct attack by the human immune system in vitro.
+Vote!
bizjournals (Free subscription) | 06/12/2008
A Geron Corp. heart failure treatment derived from human embryonic stem cells did well in early tests of how likely it is to avoid being attacked by a patient's immune system. (GERN)
+Vote!
The San Francisco Business Times (Free subscription) | 06/12/2008
A Geron Corp. heart failure treatment derived from human embryonic stem cells did well in early tests of how likely it is to avoid being attacked by a patient's immune system. (GERN)
+Vote!
Red Orbit (Free subscription) | 06/12/2008
Geron Corporation (Nasdaq:GERN) today announced the presentation of research studies indicating that GRNCM1, the company's human embryonic stem cell (hESC)-based therapeutic for the treatment of heart failure, evades direct attack by the human immune system in vitro.
+Vote!
Business Wire (Free subscription) | 06/12/2008
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the presentation of research studies indicating that GRNCM1, the company’s
+Vote!
Business Wire (Free subscription) | 06/02/2008
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced two presentations of its anti-cancer drug, GRN163L, given at the American Society of Clinical Oncology
+Vote!
adn.com: Business (Free subscription) | 7 hours ago
"We will be fortunate to make the forecast, but pinks could make up for a lot quickly," said Geron Bruce, deputy director of the state Commercial Fisheries Division. "We're at a really critical point right now, transitioning from sockeye and early chum runs to pink salmon, and some later sockeye fisheries and then cohos."
+Vote!
Red Orbit (Free subscription) | 07/10/2008
Mr. Richard Haiduck, who has been working with the company in a strategic consulting role, has been appointed as Chief Business Advisor, with responsibility for Cytopia's global business and corporate development. Mr. Haiduck has over 25 years of extensive experience with prominent life sciences companies, including Abbott, Geron, Desmos, and BioStreet, and most recently as Managing Director...
+Vote!
Autopia (Free subscription) | 07/16/2008
... by the National Institute of Aging, National Institute of Allergy and Infectious Disease, the Geron Corp. and TA Therapeutics, Ltd." (((Imagine the futurist Outquisition joy if this freakin' thing really works... "I can't afford a house, a car or a gallon o' gas, but gaw dammit, I'll live forever!")))
+Vote!
TINSEL GURUS (Free subscription) | 07/03/2008
We also have the movie dates and timing, all for our london viewers out there...waddup y'all. Love Story 2050Drama/Musical/Romance/Science fiction - Hindi - IMDb Cineworld Staples Corner Geron Way, London, NW2 6LW, UK - Map 20:40 Vue Cinemas Croydon Grant's 14 High St., Croydon, CR0 1GT, UK - Map 12:40 16:20 20:00 Vue Cinemas Acton Western Ave., London, W3 0PA, UK - Map 20:00 Vue Cinemas Harrow...
+Vote!
Business Wire (Free subscription) | 06/19/2008
... jurisdictions where such rights are available.About Start LicensingStart is a joint venture of Geron Corporation (Nasdaq: GERN) and Exeter Life Sciences, Inc. Start manages and licenses a broad portfolio of intellectual property rights related to animal reproductive technologies, including foundational nuclear transfer cloning technology developed at the Roslin Institute for the cloning...
+Vote!
bioethics.com (Free subscription) | 06/26/2008
... and Drug Administration approval to begin clinical trials next year for both sets of patients. Geron has been making the same “next year, human trials” claim for years . Yet, the FDA does not appear close to approving human trials. And here comes the usual junk biology: Those stem cells originated from newly fertilized eggs that were discarded by a fertility clinic after the egg donors no...
+Vote!
Pimm - Partial immortalization (Free subscription) | 06/13/2008
The Wall Street Journal Patent Board Biotechnology Scorecard was published this week in which biotech companies & private research firms are grouped by their Patent Board science strength ranking “which is based on the scale, quality, impact, and nearness to core science of a company’s patent-based intellectual property” . What I found interesting at the first sight is Geron’s nice position...
